ClinicalTrials.gg
RecruitingNCT06454149HUG-MALTomaUpdated Sep 28, 2026

Cohort Study for Gastric MALT Lymphoma

An observational study in Gastric MALT Lymphoma, sponsored by Seoul National University Hospital. Recruiting at 3 sites in South Korea. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Seoul National University Hospital · Observational

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Korea, Republic of — 6 open to participants now, 10 under way, 3 of them phase 3. Lymphoma, B-Cell, Marginal Zone · Korea, Republic of.

Started
2024
with 1 other
Observational
4 of 33
3 open now
Registered
31st of 33
by date
Lead sponsor
4 of 33
Seoul National University Hospital

Among the 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Korea, Republic of, this one is one of 2 that started in 2024, is one of 4 observational ones, and was the 31st registered.

Lymphoma, B-Cell, Marginal Zone

875 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 111 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

6 of the 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 92 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 77 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Lymphoma, B-Cell, Marginal Zone with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this observational study is to establish clinical data and tissue repository in patients with gastric MALT lymphoma and controls.

Participants will be asked to provide clinical information and various tissues (saliva, gastric mucosa, and feces).

03

Conditions studied

  • Gastric MALT Lymphoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Eligible patients who visited participating hospital will be asked, and upon providing informed consent, will be enrolled in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

[MALT lymphoma group]

  • Newly diagnosed as gastric MALT lymphoma [Control group]
  • Patients who underwent

    1. diagnosed upper endoscopy for dyspepsia and had chronic gastritis,
    2. therapeutic upper endoscopy for gastric hyperplastic polyps, or
    3. screening upper endoscopy without any symptoms.

Exclusion criteria

Exclusion Criteria:

  • History of gastric or other
  • Use of antibiotics or probiotics within 4 weeks
  • Uncontrolled chronic illnesses
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • MALT lymphoma

    Patients who were newly diagnosed as gastric MALT lymphoma

    Other: MALT lymphoma

  • Control group

    Patients who underwent 1. diagnosed upper endoscopy for dyspepsia and had chronic gastritis, 2. therapeutic upper endoscopy for gastric hyperplastic polyps, or 3. screening upper endoscopy without any symptoms.

Interventions

  • OtherMALT lymphoma

    New diagnosis with gastric MALT lymphoma

06

What researchers measure

Primary outcomes

  1. Remission of gastric MALT lymphoma

    Remission of gastric MALT lymphoma

    Time frame: Within 3 years from diagnosis

Secondary outcomes

  1. Eradication of H. pylori infection

    Eradication of H. pylori infection

    Time frame: Within 6 month from eradication therapy

07

Study locations

2 of 3 sites recruiting
08

References and documents

Publications

  • Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jan;31(1):17-29. doi: 10.1016/j.annonc.2019.10.010. Epub 2019 Dec 4. No abstract available. PubMed 31912792 ↗
  • Di Rocco A, Petrucci L, Assanto GM, Martelli M, Pulsoni A. Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment. Cancers (Basel). 2022 Mar 29;14(7):1742. doi: 10.3390/cancers14071742. PubMed 35406516 ↗
  • Tanaka T, Matsuno Y, Torisu T, Shibata H, Hirano A, Umeno J, Kawasaki K, Fujioka S, Fuyuno Y, Moriyama T, Esaki M, Kitazono T. Gastric microbiota in patients with Helicobacter pylori-negative gastric MALT lymphoma. Medicine (Baltimore). 2021 Sep 24;100(38):e27287. doi: 10.1097/MD.0000000000027287. PubMed 34559138 ↗
  • Lemos FFB, Silva Luz M, Rocha Pinheiro SL, Teixeira KN, Freire de Melo F. Role of non-Helicobacter pylori gastric Helicobacters in helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol. 2023 Aug 28;29(32):4851-4859. doi: 10.3748/wjg.v29.i32.4851. PubMed 37701138 ↗

Individual participant data

Plan to share: No — IPD will not be shared due to data protection policy of the participating institutions.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jun 2028, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2024
First posted
Jun 12, 2024
StartActual
Jun 6, 2024
Primary completionEst.
Jun 5, 2028
CompletionEst.
Jun 5, 2031
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms, verification date, site details and references
1 update, last Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Minor edits only
    + 4 other changes: index terms, verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06454149
Collaborators
Kangbuk Samsung Hospital, Korea University Ansan Hospital
Responsible party
Cheol Min Shin (Professor, Seoul National University Hospital) — Principal investigator
First posted
Jun 12, 2024
Start date
Jun 6, 2024
Primary completion
Jun 5, 2028 (estimated)
Completion
Jun 5, 2031 (estimated)
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion